Pharmaceuticals

Biosimilars Market Growth Opportunities: Insights from 2025–2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Biosimilars Industry Compare Between 2025 And 2029?

The biosimilars market size has experienced substantial expansion in recent years. It is projected to increase from $18.65 billion in 2024 to $21.85 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.2%. The historical growth of this market can be linked to several factors, including a rise in cancer prevalence, strong economic growth in emerging markets, increased pharmaceutical R&D expenditure, higher healthcare spending, expanding government initiatives, a robust pipeline of drugs, the lower cost of biosimilars, and an increase in patent expiration.

The biosimilars market is anticipated to experience rapid growth in the coming years, with its size projected to reach $41.34 billion by 2029, reflecting a compound annual growth rate (CAGR) of 17.3%. This expansion during the forecast period is attributable to several factors, including the increasing prevalence of cancer, a rising demand for prophylaxis using granulocyte colony-stimulating factor (G-CSF), a general increase in healthcare expenditure, the substantial potential of emerging economies, ongoing technological advances, high penetration rates of biological drugs, an aging population, and improved access to healthcare. Key trends in the forecast period include a strong focus on robust research and development (R&D) activities for developing effective and innovative drugs, an emphasis on mergers and acquisitions (M&A) as growth strategies, the establishment of strategic partnerships, increasing investments, and the integration of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Which Major Market Drivers Are Shaping The Future Of The Biosimilars Market?

An increase in the occurrence of chronic conditions such as arthritis, asthma, and cancer is anticipated to be a primary driver of the biosimilars market. Contributing factors to the prevalence of chronic diseases include long working hours, limited physical activity, and unhealthy eating and drinking habits, with biosimilars increasingly utilized to treat these conditions. Biosimilars work by activating the immune system’s response against cancer cells, thereby assisting the body in eliminating them. According to a United Nations article, the proportion of global deaths attributed to chronic diseases is expected to rise to 70% of total deaths by 2030. The global burden of chronic disease is projected to reach about 60%. Therefore, the expanding prevalence of chronic diseases is foreseen to boost the demand for biosimilars, thus driving the biosimilars market.

How Is The Biosimilars Market Classified Into Different Segments?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Which Trends Are Impacting The Biosimilars Market?

Companies operating in the biosimilars market are concentrating on developing innovative products to establish a competitive advantage. AMJEVITA holds the distinction of being the first U.S. biosimilar to Humira, a medication utilized by over a million patients managing certain serious inflammatory diseases. For example, in January 2023, Amgen Inc., a US-based biotechnology firm, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now accessible in the US. AMJEVITA (40 mg) is offered at a list price (wholesale acquisition cost) that is 55% lower than the current Humira list price. Furthermore, AMJEVITA is also available at a list price 5% below Humira’s current list price.

Who Are The Prominent Global Companies Shaping The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

What Are The Regional Market Dynamics Impacting The Biosimilars Industry?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2025, By The Business Research Company

Biosimilar Growth Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795